Actively Recruiting
Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
Led by University of Alberta · Updated on 2026-05-08
50
Participants Needed
1
Research Sites
226 weeks
Total Duration
On this page
Sponsors
U
University of Alberta
Lead Sponsor
C
Canadian Institutes of Health Research (CIHR)
Collaborating Sponsor
AI-Summary
What this Trial Is About
Temporal lobe epilepsy (TLE) is a common type of epilepsy and one of the most likely to not be controlled by medication. For patients who do not respond to medication, surgery can result in a cure of seizures. Given the fact that around 50% of patients who undergo surgery are seizure free at 10 years there is a need to improve the understanding of what factors best predict surgical outcomes in order to improve our ability to select candidates for surgery. The demonstration of abnormalities in the temporal lobe on MRI is one of the best predictors of seizure free surgical outcomes. Recent studies suggest that changes in specific subregions of the hippocampus could be the strongest predictors of surgical success, however the small size of these regions, (millimeters) make them very difficult to study with standard clinical MRI. Recently new MRI methods have been developed at Wayne State University to image hippocampal blood vessels using ferumoxytol infusion. Feraheme (ferumoxytol) is a drug that is approved in the United States for the treatment of iron deficiency anemia and is currently being studied as an MRI contrast agent in 8 active clinical trials in the United States as well as a Parkinson's Disease study in Canada.
CONDITIONS
Official Title
Enhanced MRI Imaging in Healthy Participants and Participants With Epilepsy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Healthy adults aged 18 to 64 years
- Patients aged 18 to 64 years with temporal lobe epilepsy and hippocampal sclerosis confirmed by clinical MRI
You will not qualify if you...
- Non-English speakers
- Unable to provide informed consent
- Contraindications to MRI
- Age under 18 or over 65 years
- Weight over 127.5 kg
- Women who are pregnant or breastfeeding
- Known hypersensitivity to Feraheme or intravenous iron products
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
Peter S. Allen MRI Unit
Edmonton, Alberta, Canada, T6G 2R3
Actively Recruiting
Research Team
S
Sandy Arcand
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NA
Model
SINGLE_GROUP
Primary Purpose
TREATMENT
Number of Arms
1
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here